Good MorningEquity markets pulled back again on Wednesday after the FOMC minutes revealed more risks than previously feared, and the minutes cited tight labor markets and higher-than-acceptable wage inflation, among other risks to inflation. The risks could lead to additional rate hikes not priced into equities. This sets up a situation in which the FOMC outlook darkens and puts additional weight on the market. In this scenario, the top reached by the S&P 500 is the highest level investors will see until later this year or next.
The risk is centered on the FOMC again, but the driver of that risk is oil. Oil prices retreated this week but remain uptrending and are on the verge of breaking out to new highs. The market is tilted in favor of higher prices, although the data has some volatility. The odds are high that oil prices will continue to trend higher through the end of the year and lift consumer-level inflation along with it. Featured: Yours Free! Top FIVE Dividend Stocks Right Now (The Oxford Club) 
|
Markets | | | Asian shares have slipped as rising yields in the bond market on Wall Street set off expectations that high interest rates would continue in the U.S. Benchmarks fell in Tokyo, Hong Kong, Shanghai and Seoul, while rising slightly in Sydney Read the Full Story |
|
From Our PartnersImagine… having two dozen AMAZING financial minds – giving you their crypto picks, strategies, and secrets for the rest of 2023.
It's an event and I want you to be there…
Because I don't want you to miss out on what's coming next in the market.
| | Grab a FREE ticket right now on this page! |
|
Stocks | | |
Tickets. Flights. A new 72” TV. A retro jersey for your favorite player.
With just a few weeks before the National Football League (NFL) season kicks off, preparations are well underway for football fans. For some, formulating a fantasy football strategy won’t be the only resear... Read the Full Story |
|
Stocks | | |
You could think of Vita Coco Co.'s (NASDAQ: COCO) coconut water as a beach vacation in a box.
The company, which went public in October 2021, markets its coconut water in several flavors, and also sells coconut milk and coconut juice.
Its other brands include Runa, a plant-based ener... Read the Full Story |
|
From Our PartnersThis summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did. | | | | See Why AI Should Be On Every Smart Investor's Radar |
|
Markets | | | China’s government is trying to reassure jittery homebuyers after a major real estate developer missed a payment on its multibillion-dollar debt, reviving fears about the industry’s shaky finances and their impact on the struggling Chinese economy Read the Full Story |
|
Markets | | |
There is 1 thing clear in The TJX Companies (NYSE: TJX) Q2 results, and that it is hitting its stride. The off-price retailers were expected to benefit from shifting consumer habits, and they are. It took a little longer than the market first anticipated, but the signs are clear that full-price re... Read the Full Story |
|
From Our PartnersMultimillionaire trading legend Bryan Bottarelli has uncovered something rather peculiar...
A group of 9 stocks trading at an extraordinary success rate.
Better yet, one of these 9 stocks turned a 179% profit within just a few days!
See how Bryan has been using these 9 stocks to rack up win after win at his FREE training today.
>> SHOW ME THE 9 PECULIAR STOCKS | | | | PLUS... you can receive $300 worth of free gifts by attending the training! |
|
Stocks | | |
Outdoor recreation got a big boost during the pandemic as social distancing and lockdowns caused people to seek out other forms of leisure and entertainment that didn't involve human interactions.
Recreational vehicle (RV) sales skyrocketed, as evidenced by the jump in business for RV makers like... Read the Full Story |
|
Markets | | | President Joe Biden proclaimed Wednesday his administration is “turning things around” for Americans when it comes to the economy, with his signature climate, health care and tax package giving people “more breathing room” on prices and investing anew in clean energy jobs.“We're leaving nobody behin... Read the Full Story |
|
Markets | | | Coinbase said it's received regulatory approval to bring federally regulated crypto futures trading to eligible customers in the U.S., sending shares sharply higher before the opening bell Wednesday. In June, the U.S. Securities and Exchange Commission filed lawsuits against Binance and Coinbase, sa... Read the Full Story |
|
Markets | | | The rate of inflation in the U.K. fell sharply in July to a 17-month low largely on the back of lower energy prices, official figures showed Wednesday, a welcome development for hard-pressed households struggling during the cost of living crisis. The Office for National Statistics said the annual ra... Read the Full Story |
|
Markets | | |
Target (NYSE: TGT) shares surged about 10% after the Q2 earnings report was released but don’t read too much into the news. The surge is a knee-jerk reaction to a mixed report that does nothing to improve the outlook. If anything, the Q2 strengths are 1-offs that won’t persist in the f... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California. | | View Today's Stock Pick |
|
